<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> commonly consists of <z:mp ids='MP_0005317'>elevated triglyceride levels</z:mp>; <z:mpath ids='MPATH_458'>normal</z:mpath> or slightly elevated <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>)-cholesterol levels with a preponderance of small, dense <z:chebi fb="15" ids="39026">LDL</z:chebi> particles; and low <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>)-cholesterol levels with a preponderance of small, dense <z:chebi fb="17" ids="39025">HDL</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>These abnormalities are closely connected, with prolonged residence of high levels of <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich particles in the circulation favoring abnormalities in <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="17" ids="39025">HDL</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Each of these factors has been associated with <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>; each contributes directly or indirectly to atheroma formation, with small, dense <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich remnants increasing deposition of cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> in vessel walls </plain></SENT>
<SENT sid="3" pm="."><plain>This process is facilitated by reduced reverse cholesterol transport in association with low levels of <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> and abnormal <z:chebi fb="17" ids="39025">HDL</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi>-lowering therapy focused on <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> reduction is highly successful in preventing <z:hpo ids='HP_0001677'>coronary disease</z:hpo> in diabetic patients </plain></SENT>
<SENT sid="5" pm="."><plain>Additional strategies for treating the cluster of risk factors in <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> are necessary to further reduce atherosclerotic disease in this population </plain></SENT>
</text></document>